A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (IND# 12697).

Trial Profile

A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (IND# 12697).

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Cisplatin; Doxorubicin; Etoposide; Ifosfamide; Methotrexate
  • Indications Osteosarcoma
  • Focus Therapeutic Use
  • Acronyms EURAMOS-1
  • Most Recent Events

    • 25 Aug 2016 Primary endpoint has not been met. (Event-free survival), as per an article published in the Lancet Oncology.
    • 25 Aug 2016 Results published in the Lancet Oncology
    • 29 May 2015 Event free survival and overall survival results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top